Eiger sanctioned: Celladon shareholders agree merger

By Gareth Macdonald

- Last updated on GMT

Eiger buys AAV gene therapy developer Celladon (picture: iStock/jarun011)
Eiger buys AAV gene therapy developer Celladon (picture: iStock/jarun011)
Eiger Biopharmaceuticals has merged with what is left of gene therapy developer Celladon in a deal that will see the combined firm list on the NASDAQ.

The merger comes less than a year after Celladon halted development of its lead product candidate Mydicar (AAV1/SERCA2a) – a gene therapy for heart failure - after it failed to meet primary and secondary endpoints in a Phase IIb trial.

The failure began Celladon’s collapse. In the months that followed the firm laid off staff and suspended development of a stem cell-based treatment for cardiac ischemia called mSCF.

Celladon also halted development of a preclinical candidate small molecule diabetes drug targeting the enzyme SERCA2b that it had been working on in collaboration with French firm Servier.

On May 29​ Celladon CEO Krisztina Zsebo resigned.

A day later the firm announced it was seeking buyer and hired Wedbush PacGrow Healthcare as financial advisor.

Eiger’s interest in Celladon emerged last November when the privately-held biotech announced the firms had signed a merger agreement.

Phase II development cash

The deal – which was approved by Celladon shareholders on Monday​ – sees Celladon renamed as Eiger BioPharmaceuticals.

Eiger CEO David Cory said: “We are transitioning from a private company to a publicly-traded company through this merger, and significantly increasing our financial resources.”

He also said that $39.5m (€35.3m) raised from investors combined with “$26.1m in cash on Celladon's balance sheet​” had given the merged firm enough money to “support operations and enable us to advance all four Phase 2 Orphan Disease programs."

Related topics Markets & Regulations Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more